Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
68.198,35
0,70%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CNS Pharmaceuticals Inc (CNSP) CNS Pharmaceuticals Inc (CNSP) Notizie

CNSP

CNS Pharmaceuticals (CNSP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNSP
DataOraFonteTitoloSimboloCompagnia
20/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CNSPCNS Pharmaceuticals Inc
16/05/202416:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202423:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202423:28Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
06/02/202416:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
06/02/202416:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
31/01/202422:27Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CNSPCNS Pharmaceuticals Inc
22/01/202412:02Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
08/12/202323:28Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
30/11/202323:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CNSPCNS Pharmaceuticals Inc
13/10/202300:01Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
14/08/202323:12Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202314:40Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202314:39Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202323:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNSPCNS Pharmaceuticals Inc
02/05/202301:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNSPCNS Pharmaceuticals Inc
31/03/202323:05Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
29/03/202315:05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight EventNASDAQ:CNSPCNS Pharmaceuticals Inc
13/03/202312:05PR Newswire (US)CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank IssuesNASDAQ:CNSPCNS Pharmaceuticals Inc
09/03/202315:05PR Newswire (US)CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in SwitzerlandNASDAQ:CNSPCNS Pharmaceuticals Inc
14/02/202318:24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNSPCNS Pharmaceuticals Inc
07/02/202314:45PR Newswire (US)CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMNASDAQ:CNSPCNS Pharmaceuticals Inc
12/01/202314:45PR Newswire (US)CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in PolandNASDAQ:CNSPCNS Pharmaceuticals Inc
05/01/202315:05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch EventNASDAQ:CNSPCNS Pharmaceuticals Inc
03/01/202318:00PR Newswire (US)CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of DirectorsNASDAQ:CNSPCNS Pharmaceuticals Inc
08/12/202215:08PR Newswire (US)CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)NASDAQ:CNSPCNS Pharmaceuticals Inc
05/12/202214:05PR Newswire (US)CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" EventNASDAQ:CNSPCNS Pharmaceuticals Inc
05/12/202212:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:CNSPCNS Pharmaceuticals Inc
01/12/202212:12Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CNSPCNS Pharmaceuticals Inc
01/12/202204:00PR Newswire (US)CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing PriceNASDAQ:CNSPCNS Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNSP

La tua Cronologia

BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TITR
Telecom Italia
BIT
ENEL
Enel
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
PIRC
Pirelli & C
BIT
SPM
Saipem
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network